Leal, formerly known as Trialjectory, has established a predictive patient platform that offers to 1) help cancer patients navigate their treatment journey at all stages of the disease, 2) educate patients and their oncologists about all of their treatment options in a timely manner to remove barriers to care in advance and 3) enable the pharmaceutical industry to identify potential patients that could match to their trials in the future.
COTA Inc., PreciseDx, and Baptist Health South Florida announced study results validating that the artificial intelligence-enabled PreciseBreast test is equivalent to the Oncotype DX test at predicting breast cancer recurrence. The research was presented at the San Antonio Breast Cancer Symposium.
